3227 related articles for article (PubMed ID: 8815569)
1. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
2. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
3. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.
Arch Orthop Trauma Surg; 1992; 111(2):110-20. PubMed ID: 1314065
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis.
Sasahara AA; Koppenhagen K; Häring R; Welzel D; Wolf H
Br J Surg; 1986 Sep; 73(9):697-700. PubMed ID: 3530367
[TBL] [Abstract][Full Text] [Related]
5. Prevention of postoperative deep vein thrombosis by one daily injection of low molecular weight heparin and dihydroergotamine.
Baumgartner A; Jacot N; Moser G; Krähenbühl B
Vasa; 1989; 18(2):152-6. PubMed ID: 2545054
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
De A; Roy P; Garg VK; Pandey NK
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement.
Avikainen V; von Bonsdorff H; Partio E; Kaira P; Hakkinen S; Usenius JP; Kaaja R
Ann Chir Gynaecol; 1995; 84(1):85-90. PubMed ID: 7645915
[TBL] [Abstract][Full Text] [Related]
9. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
Kakkar VV; Boeckl O; Boneu B; Bordenave L; Brehm OA; Brücke P; Coccheri S; Cohen AT; Galland F; Haas S; Jarrige J; Koppenhagen K; LeQuerrec A; Parraguette E; Prandoni P; Roder JD; Roos M; Rüschemeyer C; Siewert JR; Vinazzer H; Wenzel E
World J Surg; 1997 Jan; 21(1):2-8; discussion 8-9. PubMed ID: 8943170
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.
Steiner RA; Keller K; Lüscher T; Schreiner WE
Arch Gynecol Obstet; 1989; 244(3):141-50. PubMed ID: 2544152
[TBL] [Abstract][Full Text] [Related]
12. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
[TBL] [Abstract][Full Text] [Related]
14. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.
Eriksson BI; Kälebo P; Anthymyr BA; Wadenvik H; Tengborn L; Risberg B
J Bone Joint Surg Am; 1991 Apr; 73(4):484-93. PubMed ID: 2013587
[TBL] [Abstract][Full Text] [Related]
15. [Different effectiveness of two preparations of low molecular weight heparin in patients with elective hip joint replacement].
Weber U; Koppenhagen K; Mälzer H; Matthes M
Langenbecks Arch Chir; 1991; 376(3):147-51. PubMed ID: 1651434
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic defense during the postoperative period. Clinical documentation of low molecular weight heparin.
Welzel D; Wolf H; Koppenhagen K
Arzneimittelforschung; 1988 Jan; 38(1):120-3. PubMed ID: 2835055
[TBL] [Abstract][Full Text] [Related]
17. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.
Leyvraz PF; Richard J; Bachmann F; Van Melle G; Treyvaud JM; Livio JJ; Candardjis G
N Engl J Med; 1983 Oct; 309(16):954-8. PubMed ID: 6621623
[TBL] [Abstract][Full Text] [Related]
18. Adjusted subcutaneous heparin versus heparin plus dihydroergotamine in prevention of deep vein thrombosis after total hip arthroplasty.
Leyvraz P; Bachmann F; Vuilleumier B; Berthet S; Bohnet J; Haller E
J Arthroplasty; 1988; 3(1):81-6. PubMed ID: 3361324
[TBL] [Abstract][Full Text] [Related]
19. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
20. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
